Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer
Status:
Terminated
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
This non-interventional study will be conducted in several Eastern European countries to
assess the safety, tolerability and efficacy of Aromasin® when it is administered in
real-word setting in postmenopausal women with invasive estrogen receptor positive early
breast cancer , who are disease-free after completion of 2 to 3 years of tamoxifen and
continue the treatment with Aromasin® until completion of 5 years of adjuvant hormonal
therapy, to understand how Aromasin® is used in routine clinical practice, to assess
adherence to prescribed Aromasin® treatment and to understand reasons for its early
discontinuation.